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Dear Editor, 
 Colorectal cancer (CRC) is the third most frequent cancer in humans and more than 90% of 
cases originate from colorectal adenoma.1 The malignant evolution into CRC is characterized by a 
sequential process of  genetic and epigenetic alterations in colocytes. Recently, the growing interest 
towards epigenetic regulation of gene expression, led to the identification of different potential 
epigenetic biomarkers of CRC. In particular, DNA methylation represent one of the most 
investigated biological event involved CRC development bearing potential clinical implications for 
CRC diagnosis, prognosis and response to treatment.2 
 In a recent interesting paper, Yuan and colleagues evaluated the diagnostic accuracy of stool 
DNA methylation detection for CRC and adenoma performing a meta-analysis.3 According to 
selection criteria adopted, authors included 13 studies for a total of 716 patients with CRC, 220 with 
adenoma and 414 healthy subjects. Seven studies assessed the methylation status of a single gene 
whereas 6 studies evaluated a panel of various genes. Moreover, different methylation detection 
techniques were used including methylation-specific PCR, methylation-sensitive high-resolution 
melting and microarray DNA methylation assay followed by pyrosequencing. Finally, area under 
the summary receiver operator characteristic curve values of 0.9385 and 0.9438 for adenoma and 
CRC detection were estimated, respectively, indicating a high diagnostic accuracy for fecal gene 
methylation testing.3 
Although the authors performed a meta-regression analysis that showed no effect of 
heterogeneity on diagnostic accuracy, in our opinion both underlying differences in biomarkers 
tested and in assay methods inevitably led to unreliable results. In fact, included studies were 
carried out by using 3 different techniques as many several target genes (alone or combined into 
panels) not allowing a proper results comparison. 
Considering that hundreds of genes are aberrantly methylated in the setting of CRC and 
standardized testing protocols are still required, we suggest that further meta-analysis should be 
performed with a more precise study selection criteria. 
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